Biodesix (BDSX) Q2 2025: Development Services Revenue Jumps 53% as Primary Care Push Gains Traction
BDSX’s Q2 results reinforce its dual-pronged strategy: expanding lung diagnostics reach and scaling development services partnerships. The company’s territory-based sales structure and digital ordering initiatives are yielding higher test volumes and improved operational efficiency, while the surge in contracted development services signals robust demand from biopharma partners. With a clear path to adjusted EBITDA positivity in Q4, execution risk now centers on sales force ramp and sustained productivity across both pulmonology and primary care channels.
Summary
- Primary Care Expansion Accelerates: Early results show doubling of test orders from primary care, validating the new sales approach.
- Development Services Surges: Record contracted revenue and new partnerships highlight non-clinical growth momentum.
- Profitability Inflection Looms: Management targets adjusted EBITDA break-even in Q4, hinging on field rep productivity and volume ramp.
Business Overview
Biodesix (BDSX) is a diagnostics company focused on personalized medicine, leveraging genomics, proteomics, and radiomics, underpinned by artificial intelligence, to deliver diagnostic tests for lung disease and oncology. Its core business segments are lung diagnostic testing—primarily the Notify suite for lung nodule management—and development services, which provides test development and validation for biopharma and life sciences partners. Revenue is generated through test sales to clinicians and contracted services to industry partners.
Performance Analysis
Q2 delivered 12% revenue growth year-over-year, driven by both higher lung diagnostic test volumes and a material step-up in development services. Lung diagnostic revenue, the company’s anchor, grew 8% on 9% higher test volumes, while development services revenue expanded 53%—marking a new peak in contracted business at $12.5 million, up 54% YoY. Gross margin improved 150 basis points to 80%, reflecting operational efficiencies and pricing stability despite supply cost inflation.
Operating expenses rose 15% as Biodesix invested in sales force expansion, with SG&A up 14% due to a 21% increase in field reps. R&D spending also climbed, supporting pipeline advancement and clinical study enrollment. The net loss widened 6% YoY, and adjusted EBITDA loss increased 29%, but cash burn improved sequentially. Notably, management remains confident in achieving adjusted EBITDA positivity in Q4, underpinned by expected volume and revenue leverage as the sales team reaches full strength.
- Sales Force Scale-Up: Average field reps increased to 74, with plans to reach up to 97 by year-end, supporting broader physician coverage.
- Primary Care Channel Grows: Test orders from primary care physicians rose from 4% to 9% of mix, more than doubling since pilot launch.
- Digital Ordering Drives Retention: Accounts using digital ordering see 40% higher retention, and digital ordering volume is up 63% YoY.
Development services’ outperformance and the territory-based sales model are anchoring Biodesix’s top-line growth, but the path to profitability will depend on continued sales productivity and operational discipline.
Executive Commentary
"If the tests are ordered earlier, those patients who are at higher risk of lung cancer should be referred on to the interventional pulmonologist, while lower risk patients may remain with the primary care physicians for monitoring. This feedback was instrumental in the formation and implementation of our territory-based sales strategy to engage both pulmonologists and their referral network, including primary care."
Scott Hutton, Chief Executive Officer
"Despite increases in supply costs and existing macroeconomic uncertainty, we expect gross margins to remain in the upper 70s through the rest of the year. Because of our strong gross margins and the planned and actual expansion of the sales team and the rep productivity achieved to date, we expect to achieve adjusted EBITDA positivity in the fourth quarter."
Robin Harper-Cowie, Chief Financial Officer
Strategic Positioning
1. Territory-Based Sales Model Targets Referral Networks
BDSX’s restructured sales organization now anchors each territory with a pulmonology rep, supported by primary care and associate reps. This approach is designed to capture the estimated 50% of lung nodule patients managed outside pulmonology, expanding the company’s addressable market and improving patient capture through referral pathways.
2. Digital Enablement Boosts Operational Efficiency
Digital test ordering adoption has accelerated, with a 63% YoY increase and direct impact on physician retention and compliance. The Biodesk Physician Portal and EMR integrations reduce administrative friction and improve test completion rates, addressing a key bottleneck in diagnostic workflows.
3. Development Services: Diversification and Validation
Development services is emerging as a high-growth, high-margin complement to the clinical business, with Q2 revenue up 53% and a record $12.5 million under contract. Key partnerships, such as with Thermo Fisher for companion diagnostics, validate Biodesix’s multi-omic R&D capabilities and provide revenue diversification beyond clinical testing.
4. Pipeline and Clinical Data Drive Market Credibility
Robust clinical evidence supports adoption, with new data from the CLARIFY and altitude studies, and multiple presentations at leading scientific meetings. The pipeline—including a combination proteomic/genomic MRD test and expanded Veristrat indications—positions BDSX for future growth in oncology diagnostics.
Key Considerations
BDSX’s Q2 reflected disciplined execution on sales expansion and a clear focus on operational leverage. The company’s ability to translate sales force investments into sustained test volume growth and to further scale development services will be central to achieving its profitability and growth ambitions.
Key Considerations:
- Primary Care Channel Penetration: Early momentum is promising, but long-term mix and productivity from this channel remain unproven at scale.
- Sales Rep Productivity: Management’s confidence in $1 million annualized revenue per rep is grounded in pilot data, but broad-based replication is a key watchpoint.
- Development Services Upside: Record contracted revenue and new partnerships suggest non-clinical business could drive outsized growth and margin expansion.
- Digital Ordering Leverage: Higher retention and compliance rates from digital channels offer a scalable operational advantage.
- Clinical Data Pipeline: Ongoing studies and external presentations are building the evidence base needed for payer and clinician adoption.
Risks
Execution risk centers on sales force ramp and the ability to sustain productivity across a larger, more diverse team, particularly as primary care engagement scales. Macroeconomic pressures on supply costs and potential delays in payer adoption or clinical guideline changes (such as HEDIS quality measures) could impact test volume growth. The development services business, while high growth, may be subject to biopharma budget cycles and project timing variability.
Forward Outlook
For Q3 and Q4, Biodesix guided to:
- Continued sales rep expansion, targeting 83–87 in Q3 and 93–97 in Q4
- Gross margins to remain in the upper 70s percent range
For full-year 2025, management maintained guidance:
- Total revenue of $80–85 million
Management highlighted several factors that will drive results:
- Sales force productivity and primary care channel ramp are critical to hitting volume targets
- Development services expected to see a typical Q4 uptick due to biopharma budget cycles
Takeaways
- Sales Expansion as Growth Lever: The success of the territory-based model and primary care engagement will determine the pace and sustainability of top-line growth.
- Development Services as Margin Driver: Surging contracted revenue and marquee partnerships position this segment as a strategic growth engine and margin enhancer.
- Profitability Watch: Investors should monitor sales rep productivity, digital ordering adoption, and operating expense discipline as BDSX approaches its Q4 adjusted EBITDA inflection.
Conclusion
Biodesix’s Q2 performance demonstrates tangible progress on both clinical and non-clinical fronts, with operational improvements and commercial execution supporting a clear path to profitability. The next two quarters will test the scalability of its sales force model and the durability of development services growth, both of which are pivotal to the company’s long-term trajectory.
Industry Read-Through
BDSX’s results highlight two industry-wide themes: the growing importance of primary care in diagnostics adoption and the value of diversified revenue streams through development services partnerships. The move toward digital ordering and territory-based sales structures is likely to be mirrored by other diagnostics players seeking to penetrate referral networks and improve operational efficiency. Additionally, the surge in biopharma demand for companion diagnostic validation underscores the rising strategic value of diagnostics companies with multi-omic and AI capabilities. Investors should watch for similar commercial and R&D strategies across the precision medicine and diagnostic testing landscape.